View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar Belgyógyászati Intézet, Endokrinológia Tanszék Debrecen Nagyerdei krt. 98. 4012
  • 2 Debreceni Egyetem, Általános Orvostudományi Kar Szemészeti Klinika Debrecen
  • 3 Debreceni Egyetem, Általános Orvostudományi Kar Sebészeti Intézet, Pajzsmirigy Centrum Debrecen
  • 4 Debreceni Egyetem, Általános Orvostudományi Kar Sugárterápiás Tanszék Debrecen
  • 5 Debreceni Egyetem, Általános Orvostudományi Kar Nukleáris Medicina Tanszék Debrecen
  • 6 Debreceni Egyetem, Gyógyszerésztudományi Kar Klinikai Farmakológiai Tanszék Debrecen
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az endokrin orbitopathia a Graves-kór leggyakoribb extrathyreoidalis manifesztációja. A súlyos – látást veszélyeztető – esetek kezelése a mai napig nem megoldott probléma. A szerzők a közleményben a nemzetközi ajánlásokban is szereplő, elfogadott kezelési módok bemutatása mellett az elmúlt évtizedek terápiás próbálkozásait, a közelmúlt új kezelési lehetőségeit, valamint saját klinikai tapasztalataikat foglalják össze. Kiemelik, hogy az endokrin orbitopathia kezelésében a biológiai terápiák közül elsősorban az anti-CD20 antitesttel végzett terápiával kedvező irodalmi adatok állnak rendelkezésre. A szelén enyhe esetekben egyértelműen pozitív hatású. További, nagyobb esetszámú prospektív vizsgálatok szükségesek a biológiai terápiák alkalmazhatóságáról endokrin orbitopathiában. Orv. Hetil., 2014, 155(33), 1295–1300.

  • Weetman, A. P.: Graves’ disease. N. Engl. J. Med., 2000, 343(17), 1236–1248.

  • Brent, G. A.: Graves’ disease. N. Engl. J. Med., 2008, 358(24), 2594–2605.

  • Bartalena, L., Tanda, M. L.: Graves’ ophthalmopathy. N. Engl. J. Med., 2009, 360(10), 994–1001.

  • Metcalfe, R. A., Weetman, A. P.: Stimulation of extraocular muscle fibroblasts by citokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin. Endocrinol. (Oxf.), 1994, 40(1), 67–72.

  • Burch, H. B., Lahiri, S., Bahn, R. S., et al.: Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp. Eye Res., 1997, 65(2), 311–316.

  • Hofbauer, L. C., Mühlberg, T., König, A., et al.: Soluble interleukin-1-receptor antagonist serum levels in smokers and nonsmokers with Graves’ ophtalmopathy undergoing orbital radiotherapy. J. Clin. Endocrinol. Metab., 1997, 82(7), 2244–2247.

  • Mengistu, M., Lukes, Y. G., Nagy, E. V., et al.: TSH receptor gene expression in retroocular fibroblasts. J. Endocrinol. Invest., 1994, 17(6), 437–441.

  • Bahn, R. S.: Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy. Thyroid, 2002, 12(3), 193–195.

  • Prabhakar, B. S., Bahn, R. S., Smith, T. J.: Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr. Rev., 2003, 24(6), 802–835.

  • Bahn, R. S.: Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J. Clin. Endocrinol. Metab., 2003, 88(5), 1939–1946.

  • Mourits, M. P., Prummel, M. F., Wiersinga, W. M., et al.: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol., 1997, 47(1), 9–14.

  • Galuska, L., Leovey, A., Szucs-Farkas, Z., et al.: Imaging of disease activity in Graves’ orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl. Med. Commun., 2005, 26(5), 407–414.

  • Ujhelyi, B., Erdei, A., Galuska, L., et al.: Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves’ ophtalmopathy. Thyroid, 2009, 19(4), 375–380.

  • Bartalena, L., Baldeschi, L., Dickinson, A., et al.: Consensus statement of European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol., 2008, 158(3), 273–285.

  • Bartalena, L., Pinchera, A., Marcocci, C.: Management of Graves ophthalmopathy: reality and perspectives. Endocr. Rev., 2000, 21(2), 168–199.

  • Bartalena, L.: Prevention of Graves’ ophthalmopathy. Best Pract. Res. Clin. Endocrinol. Metab., 2012, 26(3), 371–379.

  • Lazarus, J. H., Bartalena, L., Marcocci, C., et al.: Glucocorticoid administration for Graves’ hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. J. Endocrinol. Invest., 2010, 33(6), 409–413.

  • Leövey, A., Bakó, G., Szabó, J., et al.: Combined cyclosporin-A and methylprednisolone treatment of Graves’ ophthalmopathy. Acta Med. Hung., 1992–1993, 49(3–4), 179–185.

  • Prummel, M. F., Mourits, M. P., Berghout, A., et al.: Prednisone and cyclosporine in the treatment of severe Graves’ ophtalmopathy. N. Engl. J. Med., 1989, 321(20), 1353–1359.

  • Chang, T. C., Yao, W. C., Chang, C. C.: Octreotide and urinary glucosaminoglycan in Graves’ disease. Br. Med. J., 1992, 304(6839), 1444.

  • Dickinson, A. J., Vaidya, B., Miller, M., et al.: Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophtalmopathy. J. Clin. Endocrinol. Metab., 2004, 89(12), 5910–5915.

  • Seppel, T., Schlaghecke, R., Becker, A., et al.: High dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy. Clin. Exp. Rheumatol., 1996, 14(Suppl. 15), S109–S114.

  • Kahaly, G., Pitz, S., Müller-Forell, W., et al.: Randomized trial of intravenous immunoglobulins versus prednisolone in Graves’ ophtalmopathy. Clin. Exp. Immunol., 1996, 106(2), 197–202.

  • Bouzas, E. A., Karadimas, P., Mastorakos, G., et al.: Antioxidant agents in the treatment of Graves’ ophthalmopathy. Am. J. Ophthalmol., 2000, 129(5), 618–622.

  • Balázs, C., Kiss, E., Vamos, A., et al.: Beneficial effect of pentoxiphylline on thyroid associated ophtalmopathy (TAO): a pilot study. J. Clin. Endocinol. Metab., 1997, 82(6), 1999–2002.

  • Pescovitz, M. D.: Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant., 2006, 6(5 Pt 1), 859–866.

  • Nadler, L. M., Ritz, J., Hardy, R., et al.: An unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest., 1981, 67(1), 134–140.

  • Maloney, D. G., Smith, B., Appelbaum, F. R.: The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines. Blood, 1996, 88(Suppl. 1), 637a.

  • Salvi, M., Vannucchi, G., Campi, I., et al.: Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol., 2006, 154(4), 511–517.

  • El Fassi, D., Nielsen, C. H., Hasselbalch, H. C., et al.: Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid, 2006, 16(7), 709–710.

  • El Fassi, D., Clemmensen, O., Nielsen, C. H., et al.: Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease. J. Clin. Endocrinol. Metab., 2007, 92(10), 3762–3763.

  • El Fassi, D., Nielsen, C. H., Bonnema, S. J., et al.: B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J. Clin. Endocrinol. Metab., 2007, 92(5), 1769–1772.

  • Salvi, M., Vannucchi, G., Campi, I., et al.: Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol., 2007, 156(1), 33–40.

  • Datta, S. K.: Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat. Clin. Pract. Rheumatol., 2009, 5(2), 80–82.

  • Heemstra, K. A., Toes, R. E., Sepers, J., et al.: Rituximab in relapsing Graves’ disease, a phase II study. Eur. J. Endocrinol., 2008, 159(5), 609–615.

  • El Fassi, D., Banga, J. P., Gilbert, J. A., et al.: Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin. Immunol., 2009, 130(3), 252–258.

  • Khanna, D., Chong, K. K., Afifiyan, N. F., et al.: Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophtalmology, 2010, 117(1), 133–139.e2.

  • Mitchell, A. L., Gan, E. H., Morris, M., et al.: The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy. Clin. Endocrinol., 2013, 79(3), 437–442.

  • Savino, G., Balia, L., Colucci, D., et al.: Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series. Minerva Endocrinol., 2013, 38(2), 173–179.

  • Stan, M. N., Garrity, J. A., Thapa, P., et al.: Randomized double-blind placebo-controlled trial of rituximab for treatment of Graves’ ophtalmopathy. Thyroid, 2013, 23(Suppl. 1), A13–A14.

  • Durrani, O. M., Reuser, T. Q., Murray, P. I.: Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit, 2005, 24(2), 117–119.

  • Komorowski, J., Jankiewicz-Wika, J., Siejka, A., et al.: Monoclonal anti-TNF-alpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin. Oczna, 2007, 109(10–12), 457–460.

  • Paridaens, D., van den Bosch, W. A., van der Loos, T. L., et al.: The effect of etanercept on Graves ophtalmopathy: a pilot study. Eye, 2005, 19(12), 1286–1289.

  • Smith, T. J., Hegedüs, L., Douglas, R. S.: Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract. Res. Clin. Endocrinol. Metab., 2012, 26(3), 291–302.

  • Marcocci, C., Kahaly, G. J., Krassas, G. E., et al.: Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med., 2011, 364(20), 1920–1931.